Tempus announces companion diagnostic collaboration with tscan therapeutics

Chicago--(business wire)--tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (cdx) test with tscan therapeutics, a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of cancer patients. the collaboration supports tscan's screening protocol for its phase 1 solid tumor clinical trial which is designed to enable custo.
TCRX Ratings Summary
TCRX Quant Ranking